AU2008240119B2 - Diazo bicyclic Smac mimetics and the uses thereof - Google Patents

Diazo bicyclic Smac mimetics and the uses thereof Download PDF

Info

Publication number
AU2008240119B2
AU2008240119B2 AU2008240119A AU2008240119A AU2008240119B2 AU 2008240119 B2 AU2008240119 B2 AU 2008240119B2 AU 2008240119 A AU2008240119 A AU 2008240119A AU 2008240119 A AU2008240119 A AU 2008240119A AU 2008240119 B2 AU2008240119 B2 AU 2008240119B2
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
formula
cancer
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008240119A
Other languages
English (en)
Other versions
AU2008240119A1 (en
Inventor
Qian Cai
Jianfeng Lu
Zaneta Nikolovska-Coleska
Yuefeng Peng
Su Qiu
Haiying Sun
Shaomeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39864640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008240119(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2008240119A1 publication Critical patent/AU2008240119A1/en
Application granted granted Critical
Publication of AU2008240119B2 publication Critical patent/AU2008240119B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
AU2008240119A 2007-04-13 2008-04-14 Diazo bicyclic Smac mimetics and the uses thereof Ceased AU2008240119B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92334807P 2007-04-13 2007-04-13
US60/923,348 2007-04-13
PCT/US2008/060215 WO2008128171A2 (en) 2007-04-13 2008-04-14 Diazo bicyclic smac mimetics and the uses thereof

Publications (2)

Publication Number Publication Date
AU2008240119A1 AU2008240119A1 (en) 2008-10-23
AU2008240119B2 true AU2008240119B2 (en) 2012-04-05

Family

ID=39864640

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008240119A Ceased AU2008240119B2 (en) 2007-04-13 2008-04-14 Diazo bicyclic Smac mimetics and the uses thereof

Country Status (22)

Country Link
US (2) US8278293B2 (OSRAM)
EP (1) EP2139490B1 (OSRAM)
JP (1) JP5416089B2 (OSRAM)
KR (1) KR101081685B1 (OSRAM)
CN (1) CN101686981B (OSRAM)
AU (1) AU2008240119B2 (OSRAM)
BR (1) BRPI0810522B8 (OSRAM)
CA (1) CA2683318C (OSRAM)
CY (1) CY1115735T1 (OSRAM)
DK (1) DK2139490T3 (OSRAM)
EA (1) EA017797B1 (OSRAM)
ES (1) ES2504216T3 (OSRAM)
HR (1) HRP20140885T1 (OSRAM)
HU (1) HUE024142T2 (OSRAM)
IL (1) IL201474A (OSRAM)
MX (1) MX2009011069A (OSRAM)
NZ (1) NZ580468A (OSRAM)
PL (1) PL2139490T3 (OSRAM)
PT (1) PT2139490E (OSRAM)
SI (1) SI2139490T1 (OSRAM)
WO (1) WO2008128171A2 (OSRAM)
ZA (1) ZA200907055B (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
CA2564872C (en) 2005-10-25 2010-12-21 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
SI2139490T1 (sl) * 2007-04-13 2014-11-28 The Regents Of The University Of Mchigan Office Of Technology Transfer, University Of Michigan Diazo bicikliäśni smac mimeti in njih uporaba
ES2643233T3 (es) * 2009-10-23 2017-11-21 The Regents Of The University Of Michigan Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos
EP2496606A2 (en) * 2009-11-05 2012-09-12 The UAB Research Foundation Treating basal-like genotype cancers
EP3263583A1 (en) 2010-02-12 2018-01-03 Pharmascience Inc. Iap bir domain binding compounds
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN104718209A (zh) * 2012-08-23 2015-06-17 密执安大学评议会 Iap蛋白的二价抑制剂和使用其的治疗方法
CA2896577C (en) 2012-11-30 2024-01-23 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
AU2013399606B2 (en) 2013-09-09 2016-09-22 Halliburton Energy Services, Inc. Activation of set-delayed cement compositions by retarder exchange
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10300074B2 (en) * 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR102564925B1 (ko) 2015-01-20 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CA3020792A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3535265A4 (en) 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
PL3689868T3 (pl) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
CN117510491A (zh) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
JP7422070B2 (ja) 2017-10-19 2024-01-25 デバイオファーム インターナショナル エス．エー． 癌の治療のための配合剤
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
MX2020010420A (es) 2018-04-04 2020-12-11 Arvinas Operations Inc Moduladores de la proteólisis y métodos asociados de uso.
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CA3109981A1 (en) 2018-09-07 2020-03-12 Arvinas Operations, Inc. Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US20220016079A1 (en) 2018-11-26 2022-01-20 Debiopharm International S.A. Combination treatment of hiv infections
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
EP3911316A1 (en) 2019-01-17 2021-11-24 Debiopharm International SA Combination product for the treatment of cancer
US12466809B2 (en) 2019-04-04 2025-11-11 Dana-Farber Cancer Institute, Inc. CDK2/5 degraders and uses thereof
CN110028508B (zh) * 2019-05-16 2021-05-28 南京华威医药科技集团有限公司 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
JP7764027B2 (ja) 2019-07-31 2025-11-05 ファイメクス株式会社 複素環化合物
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
US20250268863A1 (en) * 2019-09-25 2025-08-28 Debiopharm International Sa Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
JP2023510426A (ja) * 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
BR112023004656A2 (pt) 2020-09-14 2023-05-09 Arvinas Operations Inc Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
WO2024022275A1 (zh) * 2022-07-29 2024-02-01 苏州科睿思制药有限公司 Xevinapant的晶型及其制备方法和用途
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN118027138A (zh) * 2022-11-07 2024-05-14 南京中澳转化医学研究院有限公司 吡啶酮类化合物及其制备方法、药物组合物和应用
AR131299A1 (es) * 2022-12-09 2025-03-05 Debiopharm Int Sa Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010118A2 (en) * 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2007130626A2 (en) * 2006-05-05 2007-11-15 The Regents Of The University Of Michigan Bivalent smac mimetics and the uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2005504043A (ja) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
CA2553874A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006010119A2 (en) 2004-07-09 2006-01-26 Michael Norris Cargo retaining device for use in vehicle cargo storage areas
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
SI2139490T1 (sl) * 2007-04-13 2014-11-28 The Regents Of The University Of Mchigan Office Of Technology Transfer, University Of Michigan Diazo bicikliäśni smac mimeti in njih uporaba
US8445473B2 (en) * 2008-04-11 2013-05-21 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
US8625740B2 (en) * 2011-04-14 2014-01-07 Morpho Detection, Inc. System and method for correcting X-ray diffraction profiles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010118A2 (en) * 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2007130626A2 (en) * 2006-05-05 2007-11-15 The Regents Of The University Of Michigan Bivalent smac mimetics and the uses thereof

Also Published As

Publication number Publication date
HRP20140885T1 (hr) 2014-11-21
DK2139490T3 (da) 2014-09-08
CN101686981B (zh) 2013-04-10
US8278293B2 (en) 2012-10-02
BRPI0810522A2 (pt) 2014-10-21
SI2139490T1 (sl) 2014-11-28
HUE024142T2 (en) 2016-02-29
HK1141456A1 (en) 2010-11-12
EP2139490A4 (en) 2010-10-27
EA200901400A1 (ru) 2010-04-30
CN101686981A (zh) 2010-03-31
NZ580468A (en) 2012-02-24
PT2139490E (pt) 2014-10-08
JP5416089B2 (ja) 2014-02-12
US8664212B2 (en) 2014-03-04
CA2683318A1 (en) 2008-10-23
BRPI0810522B1 (pt) 2020-02-04
EP2139490A2 (en) 2010-01-06
WO2008128171A3 (en) 2008-12-11
EP2139490B1 (en) 2014-07-02
WO2008128171A2 (en) 2008-10-23
KR101081685B1 (ko) 2011-11-09
EA017797B1 (ru) 2013-03-29
JP2010523722A (ja) 2010-07-15
CY1115735T1 (el) 2017-01-25
MX2009011069A (es) 2009-12-03
PL2139490T3 (pl) 2014-11-28
AU2008240119A1 (en) 2008-10-23
BRPI0810522B8 (pt) 2021-05-25
ZA200907055B (en) 2011-03-30
IL201474A (en) 2015-11-30
KR20100005213A (ko) 2010-01-14
IL201474A0 (en) 2010-05-31
US20120309961A1 (en) 2012-12-06
ES2504216T3 (es) 2014-10-08
CA2683318C (en) 2012-10-30
US20100273812A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
AU2008240119B2 (en) Diazo bicyclic Smac mimetics and the uses thereof
AU2007248473B2 (en) Bivalent Smac mimetics and the uses thereof
US7674787B2 (en) Conformationally constrained Smac mimetics and the uses thereof
US7932382B2 (en) Conformationally constrained Smac mimetics and the uses thereof
US8202902B2 (en) Bivalent SMAC mimetics and the uses thereof
US8445473B2 (en) Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
US20100093645A1 (en) SMAC Peptidomimetics and the Uses Thereof
HK1141456B (en) Diazo bicyclic smac mimetics and the uses thereof
HK1124536B (en) Intermediates for the preparation of bivalent smac mimetics

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired